Hot Pursuit     22-Apr-24
Biocon jumps after receiving SAHPRA approval for Tacrolimus capsules
Biocon added 3.31% to Rs 270.45 after the company has received an approval from South African Health Products Regulatory Authority (SAHPRA) for their vertically integrated, complex drug product Tacrolimus capsule in South Africa.
Tacrolimus, a calcineurin inhibitor, is an immunosuppressant used in the treatment of organ transplant patients which reduces the body’s ability to reject a transplanted organ. It has been particularly effective in treating patients of renal transplant for more than two decades.

Biocon is an innovation led global biopharmaceuticals company, engaged in the production of therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development.

The company had reported consolidated net profit of Rs 660 crore in Q3 FY24 as compared with net loss of Rs 41.8 crore posted in Q3 FY23. Revenue from operations jumped 34.43% year on year (YoY) to Rs 3,953.7 crore in the quarter ended 31 December 2023.

Previous News
 ( Results - Analysis 17-May-24   10:41 )
  Biocon Ltd up for five straight sessions
 ( Hot Pursuit - 19-Feb-24   13:00 )
  Biocon to declare Quarterly Result
 ( Corporate News - 11-Jan-24   11:42 )
  Biocon acquires facility of Eywa Pharma in US for $7.7 mln
 ( Hot Pursuit - 02-Sep-23   14:59 )
  Biocon inks pact with Medix to commercialize weight mgmt product
 ( Hot Pursuit - 13-May-24   08:05 )
  Stock Alert: Indegene, Wipro, Biocon, HUDCO
 ( Market Commentary - Stock Alert 13-May-24   08:28 )
  Biocon 's biologics subsidiary gets European Commission's nod for Aflibercept biosimilar
 ( Hot Pursuit - 21-Sep-23   09:24 )
  Biocon Ltd drops for fifth straight session
 ( Hot Pursuit - 23-Feb-23   13:35 )
  Biocon's Bangalore-based API facility gets GMP certificate from German authority
 ( Hot Pursuit - 09-Jun-23   09:24 )
  Biocon Ltd rises for third consecutive session
 ( Hot Pursuit - 24-Apr-24   13:05 )
  Biocon slips after reporting net loss of Rs 42 cr in Q3
 ( Hot Pursuit - 15-Feb-23   11:58 )
Other Stories
  Eureka Forbes records over 31% YoY jump in Q4 PAT; EBITDA margin at 9.5%
  29-May-24   17:24
  Power Mech bags its first construction contract from BHEL worth Rs 563 crore
  29-May-24   16:57
  Samvardhana Motherson hits 52-week high as Q4 PAT doubles YoY; board to raise Rs 5,000 cr
  29-May-24   16:52
  Ipca Labs slides as Q4 PAT drops 22% YoY to Rs 60 cr
  29-May-24   16:46
  Mazagon Dock hits life high as Q4 PAT doubles to Rs 662 cr; order book at Rs 38,561 cr
  29-May-24   16:37
  ICRA upgrades Adani Total Gas LT rating to "AA" with 'stable' outlook
  29-May-24   16:20
  Alkem Lab PAT soars to Rs 294 cr in Q4
  29-May-24   15:45
  Emami Q4 PAT rises 3% YoY to Rs 149 cr
  29-May-24   15:37
  Medplus Health Q4 PAT rises 26% to Rs 33 cr
  29-May-24   15:02
  MTAR Technologies Ltd leads losers in 'A' group
  29-May-24   15:00
Back Top